Skip to Content

'
Gerald S. Falchook, M.D.

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Associate Member of the Graduate Faculty, Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX

Research Interests

  • Phase I studies
  • Drug development
  • Clinical trial design
  • Angiogenesis
  • Proteasome inhibition
  • Targeted therapy

Clinical Interests

Targeted therapy

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Boulevard
Unit Number: Unit 455
Houston, TX 77030
Room Number: FC8.3022
Email: gfalchoo@mdanderson.org

Education & Training

Degree-Granting Education

2009 University of Texas Health Science Center Graduate School of Biomedical Sciences, Houston, TX, MS, Cancer Biology
2001 Louisiana State University School of Medicine, New Orleans, LA, MD, Medicine
1997 Rice University, Houston, TX, BA, Biochemistry, Biology, History

Postgraduate Training

11/2007-12/2007 Externship, National Cancer Institute, Cancer Therapy Evaluation Program (NCI-CTEP), Bethesda, MD
7/2005-6/2008 Clinical Fellowship, Medical Oncology and Hematology, The University of Texas MD Anderson Cancer Center, Houston, TX
6/2001-6/2004 Clinical Residency, Internal Medicine, Baylor College of Medicine, Houston, TX

Board Certifications

2008 Medical Oncology
2004 American Board of Internal Medicine

Experience/Service

Administrative Appointments/Responsibilities

Committee Member, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, Clinical Research Advisory Committee (CRAC) UT MD Anderson Cancer Center, Houston, TX, 9/2012-present
Associate Medical Director, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, Clinical Translational Research Center (CTRC), Houston, TX, 9/2012-present
Co-director, ICT Clinical Studies Meeting, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2011-present

Other Appointments/Responsibilities

Inpatient Liaison, The University of Texas MD Anderson Cancer Center, Houston, TX, 10/2008-present

Institutional Committee Activities

Member, Faculty Senate Research Affairs Committee, 7/2011-present
Member, Faculty Senate Ad-hoc Committee for the Revisions of Research Compliance Plan, 7/2011-present
Member, eResearch Executive Steering Committee, 2/2011-present
Representative, Faculty Senate, 9/2009-present
Member, ICT Protocol Selection Steering Committee, 1/2009-present
Member, Clinical Research Committee (CRC) 2, 2009-present
Member, ASCO Young Investigator Oversight Committee, 2008-present
Member, Scientific Publications Advisory Board, 2006-present

Selected Publications

Peer-Reviewed Original Research Articles
1. Falchook GS, Janku F, Tsao AS, Bastida CC, Stewart DJ, Kurzrock R. Non-small cell lung cancer wtih HER2 exon 20 mutation: regression with dual HER2 inhibition and anti-VEGF combination treatment. J Thorac Oncol 8(2):e19-20, 10.1097/JTO.0b013e31827ce38e, 2/2013. e-Pub 2/2013. PMID: 23328556.
2. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA, Falchook G, Algazi A, Lewis K, Long GV, Puzanov I, Lebowitz P, Singh A, Little S, Sun P, AllredA, Ouellet D, Kim KB, Patel K, Weber J. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. New England Journal of Medicine 367(18):1694-703, DOI: 10.1056/NEJM0a1210093, 11/2012. PMID: 23020132.
3. Falchook GS, Lewis KD, Infante JR, Gordon MS, Vogelzang NJ, Demarini DJ, Sun P, Moy C, Szabo SA, Roadcap LT, Peddareddigari VG, Lebowitz PF, Le NT, Burris HA, Messersmith WA, O'Dwyer PJ, Kim KB, Flaherty K, Bendell JC, Gonzalez R, Kurzrock R, Fecher LA. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol 13(8):782-789, 8/2012. e-Pub 7/2012. PMID: 22805292.
4. Infante JR, Fecher LA, Falchook GS, Nallapareddy S, Gordon MS, Becerra C, Demarini DJ, Cox DS, Xu Y, Morris SR, Peddareddigari VG, Le NT, Hart L, Bendell JC, Eckhardt G, Kurzrock R, Flaherty K, Burris HA, Messersmith WA. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase I dose-escalation trial. Lancet Oncol 13(8):773-781, 8/2012. e-Pub 7/2012. PMID: 22805291.
5. Falchook GS, Duvic M, Hong DS, Wheler J, Naing A, Lim J, Kurzrock R. Age-stratified phase I trial of a combination of bortezomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignancies. Cancer Chemother Pharmacol 69(5):1117-26, 5/2012. e-Pub 12/2011. PMID: 22205203.
6. Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP, Hamid O, Infante JR, Millward M, Pavlick AC, O'Day SJ, Blackman SC, Curtis CM, Lebowitz P, Ma B, Ouellet D, Kefford RF. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase I dose-escalation trial. The Lancet 379(9829):1893-1901, 05/19/2012, 5/2012. PMID: 22608338.
7. Hong DS, Vence L, Falchook G, Radvanyi LG, Liu C, Goodman V, Legos JJ, Blackman S, Scarmadio A, Kurzrock R, Lizee G, Hwu P. BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency. Clin Cancer Res 18(8):2326-35, 4/2012. e-Pub 2/2012. PMID: 22355009.
8. Hayes TG, Falchook GS, Varadhachary A. Phase IB trial of oral talactoferrin in the treatment of patients with metastatic solid tumors. Invest New Drugs 28(2):156-62, 4/2010. e-Pub 2/2009. PMID: 19238327.
9. Falchook GS, Vega F, Dang NH, Samaniego F, Rodriguez MA, Champlin RE, Hosing C, Verstovsek S, Pro B. Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment. Ann Oncol 20(6):1080-5, 6/2009. e-Pub 2/2009. PMID: 19237479.
10. Falchook GS, Varadhachary GR, Wolff RA. Clinicopathologic features and treatment strategies for patients with pancreatic adenocarcinoma and ovarian metastases. Gynecol Oncol 108(3):515-9, 2008. PMID: 18164378.

Last updated: 3/5/2013